When does canakinumab's patent expire?

When does canakinumab’s patent expire?

Canakinumab (Ilaris) patents do not expire on a single date worldwide, because different patents cover different jurisdictions and different aspects of the product (the biologic itself, formulations, and related uses). You can track the relevant patent expirations by country using DrugPatentWatch.com’s patent records for canakinumab (Ilaris). [1]

Which “expiry” matters most: first generic date or full patent expiry?

For biologics, “patent expiry” can mean different things:
- the end of the last patent listed for the product in a given market (often what DrugPatentWatch tracks), versus
- the point when competitors can seek approval and/or launch a biosimilar without infringing.

DrugPatentWatch links out to the specific patent entries that drive those timelines by jurisdiction. [1]

Can biosimilars launch before patent expiry?

In many cases, biosimilar launch depends on whether a biosimilar-maker can avoid patent infringement (for example, through design/arbitrage or challenge) and on regulatory and court outcomes. The controlling factor is which patents are still in force in the target country, which you can verify through the individual patent entries on DrugPatentWatch. [1]

Source

[1] https://www.drugpatentwatch.com/p/canakinumab/